Exploring how a protein affects immune cells that fight melanoma
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
This study is looking at how a protein called Fgl2 affects immune cells that help fight melanoma, a serious skin cancer, to find ways to make cancer treatments work better for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Allen Institute NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-11142784 on NIH RePORTER |
What this research studies
This research investigates the role of a protein called fibrinogen-like protein 2 (Fgl2) in regulating immune cells known as CD8+ T cells, which are crucial for fighting melanoma, a deadly skin cancer. The study aims to understand how Fgl2 interacts with these T cells and influences their survival and effectiveness in attacking tumors. By using mouse models, researchers will explore the cellular and molecular mechanisms involved, which could lead to new strategies for enhancing the immune response against melanoma. The ultimate goal is to improve cancer immunotherapy outcomes for patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with melanoma who are seeking innovative treatment options.
Not a fit: Patients with non-melanoma skin cancers or those who are not eligible for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved immunotherapy treatments for melanoma patients, enhancing their immune response against tumors.
How similar studies have performed: Previous research has shown promising results in enhancing immune responses through similar mechanisms, indicating potential for success in this approach.
Where this research is happening
Seattle, United States
- Allen Institute — Seattle, United States (Active)
Researchers
- Principal investigator: Bennion, Kelsey — Allen Institute
- Study coordinator: Bennion, Kelsey
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.